enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
Hoth Therapeutics seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes upcoming events, presentations and financial documents.
Hoth Therapeutics is a development stage biopharmaceutical company focused on unique therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. To treat indications impacting more than 32 million Americans, Hoth is working to develop and commercialize the BioLexa Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform has achieved positive results at preclinical studies conducted at the University of Miami.